There were 655 press releases posted in the last 24 hours and 153,990 in the last 365 days.

Global Immuno-Oncology Diagnostics Markets & Forecasts, 2010-2016 & 2019-2023 - Outcome Potential, Companion Diagnostics, Funding, Technology Environment & Target Solutions

/EIN News/ -- Dublin, April 16, 2019 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Diagnostics: The Race for Biomarkers - Market Forecasts for Immuno-Oncology Diagnostics - With Executive and Consultant Guides and including Customized Forecasting and Analysis (2019 to 2023)" report has been added to's offering.

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size

Key Topics Covered:

i. Market Guides
iA. Situation Analysis
iB. Guide for Executives and Marketing Staff
iC. Guide for Investment Analysts and Management Consultants
iD. Impact of the Nobel Prize

1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics?
1.2 Immuno-oncology - the looming cure.
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system Surface barriers Inflammation Complement system Cellular barriers Natural killer cells
2.0.2 Adaptive immune system Lymphocytes Killer T cells Helper T cells Gamma delta T cells B lymphocytes and antibodies
2.0.3 Tumor immunology - the immune surveillance system
2.1 Immuno OncologyDiagnostics
2.1.1 Checkpoint Assays
2.1.2 Cytokine Assays
2.1.3 Genomic Germline
2.1.4 Genomic Tumour
2.1.5 Tumor Microenviroment
2.1.6 Others

3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Companion Diagnostics
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role
4.2.3 Protocols
4.3 Diagnostic Technology Development
4.3.1 Combinations - Issues and Complexity
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Tumor Mutational Burden as Predictor of Immunotherapy Success
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
MolecularMD Launches Validated Tumor Mutation Burden Assay
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
Cancer Genetics Expands Immuno-Oncology Panel
10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product
Qiagen, Freenome Partner to Improve Companion Diagnostic Development
Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime
Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio
Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies
HalioDx announces high capacity IHC multiplex technology
MolecularMD to Implement Promega's Technology
NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel
MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response
Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
HalioDx Closes 18.5M Series B Round
Announcement of the 2018 Nobel Prize in Physiology or Medicine

6. Profiles of Key Immunotherapy Companies
10X Genomics
Abbott Laboratories
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
Biodesix Inc.
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River
Chronix Biomedical
Clearbridge BioMedics
Clinical Genomics
Cytolumina Technologies Corp.
Dako (Agilent)
Diagnologix LLC
Epic Sciences
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Genomic Health
Guardant Health
Horizon Discovery
HTG Molecular Diagnostics
Incell Dx
Integrated Diagnostics
Leica Biosystems
MDx Health
Merck & Co., Inc
Molecular MD
MRM Proteomics Inc
Myriad Genetics/Myriad RBM
New Oncology
Ortho Clinical Diagnostics
Perkin Elmer
Personal Genome Diagnostics
Protagen Diagnostics
Rarecells SAS
Roche Diagnostics
Silicon Biosystems
SRI International
Thermo Fisher
Vortex Biosciences

7. Global Market Size
7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts

8. Global Market by Type
8.1 Checkpoint Assay Market
8.2 Cytokine Assay Market
8.3 Genome Germline Market
8.4 Genome Tumour Market
8.5 Tumour Micro Environment Market
8.6 Other Market

9. Appendices
9.1 FDA Cancer Drug Approvals by Year
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments - 2015

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Biomarkers 


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.